QuiaPEG

Newsroom

Se nyheter från:
Page:
123456
Dec 10, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) develops improved and patentable versions of clinically validated or approved drugs, so called biobetters. This is based on the company's proprietary patent-protected technology platform, Uni-Qleaver®, which allows a chosen release time for the drug through a controllable chemical coupling unit. After receiving positive pre- clinical trial results for QPG-1029, QuiaPEG today announces that it has signed a Material Transfer Agreement (MTA) with an Asian pharmaceutical company regarding the QPG-1029 drug project (peg-liraglutid), which has blockbuster1 potential in the indications diabetes and overweight.

Nov 28, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) develops improved and patentable versions of clinically validated or approved drugs, known as biobetters. This is based on the company's proprietary patent-protected technology platform, Uni-Qleaver®, which allows selection of a release time for the drug through a controllable chemical coupling unit. After receiving positive pre-clinical trial results, the company has chosen its first drug project, peg-liraglutide (QPG- 1029), which has blockbuster1 potential for the indications diabetes and obesity.

Oct 14, 2018

The Extraordinary General Meeting of QuiaPEG Pharmaceuticals Holding AB (publ) ("the Company") decided on 29thJune 2018 to establish a warrant-based incentive program for senior executives within the QuiaPEG Group through the issue of up to 1,000,000 warrants with the right to subscribe for new shares in the Company, and approval of the transfer of such options. The warrants could only be subscribed to by the company's wholly owned subsidiary, QuiaPEG Pharmaceuticals AB ("Subsidiary"), that has the entitlement and obligation to transfer the warrants to senior executives within the QuiaPEG Group on one or more occasions in accordance with the allocation decided by the Board.

Oct 12, 2018

QuiaPEG Pharmaceuticals Holding AB (publ), which develops improved and patentable versions of clinically validated or approved drugs using the company's unique technology platform, announces that, on October 10th, 2018, Steen Krøyer, Chairman of the Board, has acquired 75,000 shares at an average price of SEK 3.18, totaling SEK 238,500.

Page:
123456
Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message